HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


WellPoint NextRx/BCBS Pilot Program Encourages Members To Buy OTC

This article was originally published in The Tan Sheet

Executive Summary

Insurers are increasingly encouraging members to use over-the-counter drugs in place of more expensive prescription options by expanding coverage plans, offering coupons or paying for a member's first supply of an OTC drug. The growing trend reflects a push to contain rising health care costs

You may also be interested in...

Prepaid Cards Could Help OTC Switches Gain Against Rx Competitors

Medagate Corp.’s payment technology that simplifies insurance reimbursement for OTCs could help level the playing field with competing prescription products.

Switch Sponsors Find Key Partners In Payers, Providers and Managed Care

Over-the-counter switch programs that engage health care professionals as partners generate two to three times the consumer awareness as those that do not, said Rohinish Hooda, VP of upper respiratory at McNeil Consumer Healthcare

Perrigo Licenses Antihistamine Levocetirizine, “Prime” Switch Candidate

Perrigo's licensing agreement with Synthon Pharmaceuticals to market a generic of UCB's antihistamine Xyzal brings the private labeler a "prime example" of an Rx-to-OTC switch candidate. Switch is a "likely scenario" for the allergy drug, Perrigo maintains

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts